Illumina Inc. has entered a definitive agreement to acquire SomaLogic from Standard BioTools in a deal valued at approximately $425 million. The transaction includes an upfront payment of $350 million. This acquisition is part of Illumina's strategic push to expand its proteomics capabilities and advance its multiomics approach, which integrates genomics and proteomics to provide a broader understanding of biology. The deal marks a key step in Illumina's transformation and growth in the biotechnology sector. Following the sale, Standard BioTools secured a $550 million war chest to support its next phase of transformation. Industry analysts view Illumina's purchase of SomaLogic as a potential tipping point for the multiomics field. Additionally, Illumina has recently enhanced its flagship assay to accelerate access to comprehensive tumor profiling, reinforcing its commitment to advancing precision medicine.